Xu Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xu Wang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Yajuan Chang
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, PR China
2 shared publicationsCheng Zhang
Xuzhou Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Xuzhou, Jiangsu, 221000, China
1 shared publication- Dongzhi Yang
Xuzhou Medical University
1 shared publication - Ling Zhu
Department of Pharmacy, The Affiliated Jiangyin Clinical College of Xuzhou Medical University, Wuxi, PR China
1 shared publication Ning Ding
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, PR China
1 shared publicationQing Yu
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, PR China
1 shared publication
Latest Publications
- 8 June 2026
- Published by Royal Society of Chemistry (RSC) in Nanoscale Horizons
- Vol. 11 (9) , 2401-2412
Enhancing photodynamic and chemodynamic therapy efficacy through a novel ROS-amplifying therapeutic platform for breast cancer treatment
Suboptimal reactive oxygen species (ROS) production in photodynamic therapy (PDT) and chemodynamic therapy (CDT) due to tumor antioxidants and H2O2 constraints poses a challenge to their therapeutic efficacy. To address this, our study introduces GOx@MPN@Gel, a novel PDT/CDT platform that integrates glucose oxidase (GOx), luteolin, iron ions, a traditional Chinese medicine-inspired metal-phenolic network (MPN), and hydrogel (Gel) carriers to enhance ROS generation. Experimental results demonstrate GOx@MPN@Gel heightened acid sensitivity, robust GOx activity, and significant ROS production. Both in vitro and in vivo tests validate its therapeutic potential. Within the tumor microenvironment, GOx@MPN@Gel effectively elevates H2O2 levels for CDT, producing cytotoxic hydroxyl radicals (·OH), and upon near infrared (NIR) light exposure, its porphyrin component triggers potent PDT effects, generating additional ROS. This synergistic approach significantly enhances antitumor efficacy. The platform's unique design, combining acid-responsive degradation and PDT/CDT synergy, offers a promising personalized treatment strategy for breast cancer.
- 8 June 2026
- Published by Royal Society of Chemistry (RSC) in Nanoscale Horizons
- Vol. 11 (9) , 2401-2412
Enhancing photodynamic and chemodynamic therapy efficacy through a novel ROS-amplifying therapeutic platform for breast cancer treatment
Suboptimal reactive oxygen species (ROS) production in photodynamic therapy (PDT) and chemodynamic therapy (CDT) due to tumor antioxidants and H2O2 constraints poses a challenge to their therapeutic efficacy. To address this, our study introduces GOx@MPN@Gel, a novel PDT/CDT platform that integrates glucose oxidase (GOx), luteolin, iron ions, a traditional Chinese medicine-inspired metal-phenolic network (MPN), and hydrogel (Gel) carriers to enhance ROS generation. Experimental results demonstrate GOx@MPN@Gel heightened acid sensitivity, robust GOx activity, and significant ROS production. Both in vitro and in vivo tests validate its therapeutic potential. Within the tumor microenvironment, GOx@MPN@Gel effectively elevates H2O2 levels for CDT, producing cytotoxic hydroxyl radicals (·OH), and upon near infrared (NIR) light exposure, its porphyrin component triggers potent PDT effects, generating additional ROS. This synergistic approach significantly enhances antitumor efficacy. The platform's unique design, combining acid-responsive degradation and PDT/CDT synergy, offers a promising personalized treatment strategy for breast cancer.
- Open Access
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
Molecularly imprinted polymer-modified carbon dots as a fluorescent probe for caffeic acid detection
A molecularly imprinted fluorescent probe (bCDs@MIP) was developed for selective detection of caffeic acid via fluorescence quenching. The method shows a LOD of 0.15 µM and was successfully applied to human serum analysis.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
Open AccessMolecularly imprinted polymer-modified carbon dots as a fluorescent probe for caffeic acid detection
A molecularly imprinted fluorescent probe (bCDs@MIP) was developed for selective detection of caffeic acid via fluorescence quenching. The method shows a LOD of 0.15 µM and was successfully applied to human serum analysis.